These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32445523)

  • 1. Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients.
    Dusheiko G
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1439-1440. PubMed ID: 32445523
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply.
    Kim GA; Lim YS
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1440-1441. PubMed ID: 32445524
    [No Abstract]   [Full Text] [Related]  

  • 3. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
    Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
    World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
    Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
    N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma.
    Chen YC; Liaw YF
    Aliment Pharmacol Ther; 2016 Jul; 44(2):210-1. PubMed ID: 27296691
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
    Jiang JF; Sun J; Shi J; Liu X
    Aliment Pharmacol Ther; 2017 May; 45(9):1286-1288. PubMed ID: 28370051
    [No Abstract]   [Full Text] [Related]  

  • 7. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients.
    Chen CH; Hung CH; Lee CM; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
    Gastroenterology; 2007 Nov; 133(5):1466-74. PubMed ID: 17915220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
    Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
    Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
    Huang R; Wang J; Yan X; Xia J; Wu C
    Aliment Pharmacol Ther; 2019 Sep; 50(5):618-619. PubMed ID: 31414546
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients.
    Bahramali G; Sadeghizadeh M; Amini-Bavil-Olyaee S; Alavian SM; Behzad-Behbahani A; Adeli A; Aghasadeghi MR; Amini S; Mahboudi F
    World J Gastroenterol; 2008 Sep; 14(35):5448-53. PubMed ID: 18803358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically.
    Song BC; Kim SH; Kim H; Ying YH; Kim HJ; Kim YJ; Yoon JH; Lee HS; Cha CY; Kook YH; Kim BJ
    J Med Virol; 2005 Jun; 76(2):194-202. PubMed ID: 15834881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Authors' reply.
    Choi GH; Lim YS
    Aliment Pharmacol Ther; 2019 Sep; 50(5):619-620. PubMed ID: 31414529
    [No Abstract]   [Full Text] [Related]  

  • 13. Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy.
    Ieluzzi D; Covolo L; Donato F; Fattovich G
    Dig Liver Dis; 2014 May; 46(5):427-32. PubMed ID: 24548819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
    Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
    J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B.
    Kim SE
    Korean J Intern Med; 2017 Jul; 32(4):631-633. PubMed ID: 28704912
    [No Abstract]   [Full Text] [Related]  

  • 16. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?
    Carlson S; Vaz K; Peterson A
    J Hepatol; 2023 Oct; 79(4):e154-e155. PubMed ID: 36736735
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
    Chun HS; Lee M
    Clin Mol Hepatol; 2021 Jul; 27(3):448-450. PubMed ID: 34157831
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
    Huang R; Liu J; Wang J; Yan X; Wu C
    Aliment Pharmacol Ther; 2021 Mar; 53(6):761-762. PubMed ID: 33599329
    [No Abstract]   [Full Text] [Related]  

  • 19. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases.
    Bréchot C; Hadchouel M; Scotto J; Fonck M; Potet F; Vyas GN; Tiollais P
    Proc Natl Acad Sci U S A; 1981 Jun; 78(6):3906-10. PubMed ID: 6267609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.
    Fattovich G; Bortolotti F; Donato F
    J Hepatol; 2008 Feb; 48(2):335-52. PubMed ID: 18096267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.